IMGT/mAb-DB card

Version: 2.0.4 (2023-04-14)

Citing IMGT/mAb-DB

Manso T., Kushwaha A., Abdollahi N., Duroux P., Giudicelli V. and Kossida S. Mechanisms of action of monoclonal antibodies in oncology integrated in IMGT/mAb-DB. Front Immunol., 14 (2023). DOI 10.3389/fimmu.2023.1129323

Poiron C., Wu Y., Ginestoux C., Ehrenmann, Duroux P. and Lefranc M.-P. IMGT/mAb-DB: the IMGT® database for therapeutic monoclonal antibodies. JOBIM 2010, Paper 13 (2010). Abstract

Cambon M., Cherouali K., Kushwaha A., Giudicelli V., Duroux P., Kossida S. and Lefranc M.-P. IMGT/mAb-DB and IMGT/2Dstructure-DB for IMGT standard definition of an antibody: from receptor to amino acid changes. JOBIM 2018, Poster 201 (2018). Abstract

IMGT/mAb-DB ID	799
INN	iscalimab
INN Number	10707
INN Prop. List	118 (2017)
INN Rec. List	80 (2018)
Common name	CFZ-533, OM11-62MF, NVP-CFZ533
Proprietary name
Species	Homo sapiens
IMGT receptor type	IG
Format (legend)
Receptor identification	IgG1 - kappa
Radiolabelled / Conjugated / Fused
IMGT/2Dstructure-DB	10707
IMGT/3Dstructure-DB
Specificity target name and species	CD40 (tumor necrosis factor receptor superfamily member 5, TNFRSF5, p50) [Homo sapiens]
Development Technology
Origin clone species
Origin clone name	NVS240705

Company	Novartis Pharmaceuticals Corp. (East Hanover NJ USA)
Expression system
Application	Therapeutic
Clinical domain	Immunology
Mechanism of action
Clinical indication	Kidney transplant rejection
Development status	Phase I/II
Regulatory agency status and year

Company	Novartis Pharmaceuticals Corp. (East Hanover NJ USA)
Expression system
Application	Therapeutic
Clinical domain	Immunology
Mechanism of action
Clinical indication	Psoriasis
Development status	Phase I
Regulatory agency status and year

Company	Novartis Pharmaceuticals Corp. (East Hanover NJ USA)
Expression system
Application	Therapeutic
Clinical domain	Immunology
Mechanism of action
Clinical indication	Myasthenia Gravis (MG)
Development status	Phase II
Regulatory agency status and year

Company	Novartis Pharmaceuticals Corp. (East Hanover NJ USA)
Expression system	CHO (Chinese Hamster Ovary) cells
Application	Therapeutic
Clinical domain	Ophthalmology
Mechanism of action
Clinical indication	Graves' orbitopathy (GO)
Development status	Phase II
Regulatory agency status and year

Company	Novartis Pharmaceuticals Corp. (East Hanover NJ USA)
Expression system
Application	Therapeutic
Clinical domain	Autoimmunity
Mechanism of action
Clinical indication	Sjögren's syndrome (SjS)
Development status	Phase II
Regulatory agency status and year

Clinical trials	12 studies found, 6 recruiting
Authority decisions
External links
Biosimilars

Format legend:

IMGT/mAb-DB query | IMGT/mAb-DB documentation